Q3 2023 · 13F-HR
Athyrium Capital Management, LPholdings as filed
Filed 2023-11-14 · accession 0001123292-23-000142
$113.6M
Reported value
6
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 682143AG7 | OMER 5.25 02/15/26 | Omeros Corp | $44.6M | 39.3% | 72,979,000 | Common | NONE |
| 74319FAB3 | — | Biora Inc. | $28.0M | 24.6% | 53,500,000 | Common | NONE |
| 74319F305 | — | Biora Inc. | $23.7M | 20.9% | 10,929,762 | Common | SOLE |
| 682143AE2 | — | Omeros Corp | $11.3M | 9.91% | 11,005,000 | Common | NONE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $4.7M | 4.15% | 1,792,114 | Common | SOLE |
| G6S41R101 | RVLPQ | RVL PHARMACEUTICALS PLC | $1.3M | 1.11% | 14,600,444 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.